name: Tay-Sachs Disease
creation_date: '2026-01-06T04:44:07Z'
updated_date: '2026-02-06T03:39:54Z'
category: Genetic
parents:
- Lysosomal Storage Disorder
- Neurodegenerative Disease
disease_term:
  preferred_term: Tay-Sachs disease
  term:
    id: MONDO:0010100
    label: Tay-Sachs disease
has_subtypes:
- name: Infantile Tay-Sachs
  description: Classic form with onset at 3-6 months, rapidly progressive, fatal by age 4-5.
- name: Juvenile Tay-Sachs
  description: Onset in childhood, slower progression, death in adolescence.
- name: Late-Onset Tay-Sachs
  description: Adult onset, variable progression, compatible with longer survival.
pathophysiology:
- name: HEXA mutations
  description: >
    Pathogenic variants in HEXA disrupt hexosaminidase A activity.
  genes:
  - preferred_term: HEXA
    term:
      id: hgnc:4878
      label: HEXA
  downstream:
  - target: Hexosaminidase A deficiency
    description: Loss of functional alpha subunit reduces enzyme activity.
  evidence:
  - reference: PMID:40710901
    supports: SUPPORT
    snippet: "Mechanistically, TSD is caused by mutations in the HEXA gene, which encodes the alpha subunit of hexosaminidase A."
    explanation: Review states Tay-Sachs disease is caused by HEXA mutations affecting hexosaminidase A.
- name: Hexosaminidase A deficiency
  description: >
    Lysosomal beta-hexosaminidase A enzyme activity is deficient in Tay-Sachs disease.
  biological_processes:
  - preferred_term: ganglioside catabolic process
    modifier: DECREASED
    term:
      id: GO:0006689
      label: ganglioside catabolic process
  downstream:
  - target: GM2 ganglioside accumulation in neurons
    description: Reduced catabolism leads to GM2 storage in neurons.
  evidence:
  - reference: PMID:19820796
    supports: SUPPORT
    snippet: "Tay-Sachs disease is an autosomal recessive disorder of sphingolipid metabolism, caused by enzyme hexosaminidase A deficiency that leads to an accumulation of GM2 in neurocytes which results in progressive loss of neurological function."
    explanation: Supports hexosaminidase A deficiency as a core defect in Tay-Sachs disease.
- name: GM2 ganglioside accumulation in neurons
  description: >
    GM2 ganglioside accumulates in neuronal lysosomes, particularly in the brain.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Neuron death
    description: Storage-related toxicity contributes to neuronal loss.
  evidence:
  - reference: PMID:22025593
    supports: SUPPORT
    snippet: "G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal Î²-hexosaminidase and result in ganglioside accumulation in the brain."
    explanation: GM2 gangliosidosis (includes Tay-Sachs) shows ganglioside accumulation in brain.
- name: Neuron death
  description: >
    Progressive neuronal loss occurs in the nervous system.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: neuron death
    term:
      id: GO:0070997
      label: neuron death
  evidence:
  - reference: PMID:29618308
    supports: SUPPORT
    snippet: "Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."
    explanation: Review describes rapid neurodegeneration in infantile GM2 gangliosidosis, consistent with neuronal loss.
phenotypes:
- name: Developmental Regression
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Loss of previously acquired milestones, typically starting at 3-6 months
  phenotype_term:
    preferred_term: Developmental Regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:25143775
    supports: SUPPORT
    snippet: "All of them had a developmental disorder as a chief complaint. 38%of patients had a history of developmental delay or regression"
    explanation: Case series confirms developmental regression as a key presenting feature in GM2 gangliosidosis patients.
  - reference: PMID:22025593
    supports: SUPPORT
    snippet: "Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
    explanation: Natural history study of 97 patients confirms developmental arrest in 83% of infantile GM2 gangliosidosis cases.
  - reference: PMID:29618308
    supports: SUPPORT
    snippet: "Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."
    explanation: Review describes developmental arrest with regression of milestones as a core feature of Tay-Sachs disease.
- name: Cherry-Red Spot
  category: Ophthalmologic
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Pathognomonic finding on fundoscopy
  phenotype_term:
    preferred_term: Cherry-Red Spot
    term:
      id: HP:0010729
      label: Cherry red spot of the macula
  evidence:
  - reference: PMID:19820796
    supports: SUPPORT
    snippet: "The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease."
    explanation: Case report describes cherry-red spot as the hallmark ophthalmologic finding in Tay-Sachs disease.
- name: Exaggerated Startle Response
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Hyperacusis with exaggerated startle to sound
  phenotype_term:
    preferred_term: Exaggerated Startle Response
    term:
      id: HP:0002267
      label: Exaggerated startle response
  evidence:
  - reference: PMID:22025593
    supports: SUPPORT
    snippet: "Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
    explanation: Natural history study of 97 patients confirms exaggerated startle response (startling) in 65% of infantile GM2 gangliosidosis patients.
  - reference: PMID:24534057
    supports: SUPPORT
    snippet: "The augmented startle reflex appeared between the age of 3 and 17 months and disappeared between the age of 4 and 6 years."
    explanation: Electrophysiological study documents the temporal evolution of the augmented startle reflex in Tay-Sachs disease.
- name: Hypotonia
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Progresses to spasticity
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:22025593
    supports: SUPPORT
    snippet: "Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
    explanation: Natural history study confirms hypotonia in 60% of infantile GM2 gangliosidosis patients at disease onset.
- name: Seizures
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:25143775
    supports: SUPPORT
    snippet: "38%of patients had a history of developmental delay or regression and 22% had seizures."
    explanation: Case series documents seizures as a clinical manifestation in GM2 gangliosidosis patients.
- name: Macrocephaly
  category: Neurological
  frequency: FREQUENT
  notes: Due to brain swelling from ganglioside accumulation
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:7732608
    supports: SUPPORT
    snippet: "Generalized hypotonia, macrocephaly, hyperacusis and a retinal cherry red spot appearance were present."
    explanation: Case report documents macrocephaly in Tay-Sachs disease.
- name: Blindness
  category: Ophthalmologic
  frequency: VERY_FREQUENT
  notes: Progressive visual loss
  phenotype_term:
    preferred_term: Blindness
    term:
      id: HP:0000618
      label: Blindness
  evidence:
  - reference: PMID:24011710
    supports: SUPPORT
    snippet: "Disorders such as Tay-Sachs or Niemann-Pick disease are the most familiar examples of dysfunction in sphingolipid metabolism and are typically associated with neurodegeneration and ocular findings such as blindness."
    explanation: Review establishes blindness as a characteristic ocular finding in sphingolipidoses including Tay-Sachs disease.
biochemical:
- name: Hexosaminidase A Activity
  presence: Decreased
  context: Absent or severely reduced in leukocytes or fibroblasts
- name: GM2 Ganglioside
  presence: Elevated
  context: Accumulates in brain tissue
genetic:
- name: HEXA
  gene_term:
    preferred_term: HEXA
    term:
      id: hgnc:4878
      label: HEXA
  association: Causative
  notes: Autosomal recessive, higher frequency in Ashkenazi Jewish population
treatments:
- name: Supportive Care
  description: Symptomatic management including seizure control, nutrition support, respiratory care.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:27491214
    supports: SUPPORT
    snippet: "Both are devastating diseases without cure or specific treatment however, with the use of supportive aggressive medical management, the lifespan and quality of life has been extended for both diseases."
    explanation: Review confirms supportive care extends lifespan and quality of life in GM2 gangliosidoses including Tay-Sachs disease.
- name: Genetic Counseling
  description: Carrier screening especially in high-risk populations.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:12108829
    supports: SUPPORT
    snippet: "Carrier testing for Tay-Sachs disease should be offered to couples when at least one individual is of Ashkenazi Jewish (carrier frequency 1/30), Pennsylvania Dutch, Southern Louisiana Cajun, or Eastern Quebec French Canadian descent."
    explanation: Review establishes carrier screening recommendations for high-risk populations including Ashkenazi Jews.
- name: Substrate Reduction Therapy
  description: Investigational approaches to reduce GM2 synthesis.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  review_notes: Needs a more specific MAXO term for substrate reduction therapy.
  evidence:
  - reference: PMID:27491214
    supports: SUPPORT
    snippet: "Treatment with FDA-approved glucose analogs to reduce the amount of ganglioside substrate is used as off-label treatments for some patients."
    explanation: Review confirms substrate reduction therapy using glucose analogs is being used off-label in GM2 gangliosidoses.
- name: Gene Therapy
  description: Experimental AAV-based gene therapy in clinical trials.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  evidence:
  - reference: PMID:35145305
    supports: SUPPORT
    snippet: "This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy."
    explanation: First-in-human AAV gene therapy trial demonstrates safety and proof-of-concept for Tay-Sachs disease treatment.
datasets:
